

Eduardo Dunayevich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11025296/publications.pdf>

Version: 2024-02-01

28
papers

3,393
citations

279487

23
h-index

500791

28
g-index

28
all docs

28
docs citations

28
times ranked

2638
citing authors

#	ARTICLE	IF	CITATIONS
1	Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials. <i>Acta Neurologica Scandinavica</i> , 2021, 143, 154-163.	1.0	20
2	Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial. <i>Epilepsia</i> , 2021, 62, 2228-2239.	2.6	52
3	Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials. <i>Epilepsia</i> , 2021, 62, 2218-2227.	2.6	14
4	Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial. <i>Epilepsia</i> , 2021, 62, 2505-2517.	2.6	45
5	Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 531-540.	1.0	33
6	Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome. <i>JAMA Neurology</i> , 2020, 77, 613.	4.5	171
7	Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis. <i>International Journal of Obesity</i> , 2019, 43, 2085-2094.	1.6	13
8	Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study. <i>Advances in Therapy</i> , 2017, 34, 2307-2315.	1.3	37
9	Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 2 – External Validity and Correlates. <i>Schizophrenia Bulletin</i> , 2015, 41, 1055-1065.	2.3	95
10	Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 1 – Psychometric Characteristics of 5 Paradigms. <i>Schizophrenia Bulletin</i> , 2015, 41, 1045-1054.	2.3	137
11	A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-1). <i>Obesity</i> , 2013, 21, 935-943.	1.5	499
12	Naltrexone/Bupropion Combination Therapy in Overweight or Obese Patients With Major Depressive Disorder. primary care companion for CNS disorders, <i>The</i> , 2013, 15, .	0.2	23
13	Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial. <i>Obesity</i> , 2011, 19, 110-120.	1.5	394
14	An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. <i>Addictive Behaviors</i> , 2010, 35, 229-234.	1.7	44
15	Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , <i>The</i> , 2010, 376, 595-605.	6.3	765
16	Comparison of Combined Bupropion and Naltrexone Therapy for Obesity with Monotherapy and Placebo. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4898-4906.	1.8	151
17	Rational Design of a Combination Medication for the Treatment of Obesity. <i>Obesity</i> , 2009, 17, 30-39.	1.5	266
18	Response to Kujawa et al. letter-to-the-editor. <i>Schizophrenia Research</i> , 2006, 84, 172-173.	1.1	1

#	ARTICLE	IF	CITATIONS
19	Characteristics of two alternative schizophrenia remission definitions: Relationship to clinical and quality of life outcomes. <i>Schizophrenia Research</i> , 2006, 86, 300-308.	1.1	38
20	The cost of treating anxiety: the medical and demographic correlates that impact total medical costs. <i>Depression and Anxiety</i> , 2005, 21, 178-184.	2.0	157
21	A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia. <i>Schizophrenia Research</i> , 2005, 79, 337-340.	1.1	32
22	Medical and productivity costs of anxiety disorders: Case control study. <i>Depression and Anxiety</i> , 2004, 19, 112-120.	2.0	80
23	A pilot study of rapid lithium administration in the treatment of acute mania. <i>Bipolar Disorders</i> , 2001, 3, 68-72.	1.1	24
24	Prevalence and description of psychotic features in bipolar mania. <i>Current Psychiatry Reports</i> , 2000, 2, 286-290.	2.1	140
25	Atypical Antipsychotics in the Treatment of Bipolar Disorder. <i>CNS Drugs</i> , 2000, 13, 433-441.	2.7	15
26	Olanzapine-Induced Tardive Dystonia. <i>American Journal of Psychiatry</i> , 1999, 156, 1662-1662.	4.0	64
27	Personality disorders in first- and multiple-episode mania. <i>Psychiatry Research</i> , 1996, 64, 69-75.	1.7	24
28	Affective state dependence of the Tridimensional Personality Questionnaire. <i>Psychiatry Research</i> , 1995, 57, 209-214.	1.7	59